Kaleido Biosciences, Inc.
KLDO
$0.002
$0.00191,900.00%
OTC PK
| 12/31/2021 | 09/30/2021 | ||||
|---|---|---|---|---|---|
| Revenue | 373.08% | -50.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 373.08% | -50.71% | |||
| Cost of Revenue | -10.55% | -1.26% | |||
| Gross Profit | 12.86% | 0.66% | |||
| SG&A Expenses | -9.58% | -11.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.97% | -3.85% | |||
| Operating Income | 12.76% | 3.42% | |||
| Income Before Tax | 12.19% | 3.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.19% | 3.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.19% | 3.37% | |||
| EBIT | 12.76% | 3.42% | |||
| EBITDA | 13.15% | 3.56% | |||
| EPS Basic | 12.23% | 3.45% | |||
| Normalized Basic EPS | 12.25% | 3.45% | |||
| EPS Diluted | 12.23% | 3.45% | |||
| Normalized Diluted EPS | 12.25% | 3.45% | |||
| Average Basic Shares Outstanding | 0.05% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||